Compounding Records - Mpje

1. A pharmacy maintains compounding records electronically. During an inspection, an investigator requests a Compounding Record from 18 months ago. The pharmacy's system requires an IT password only the IT person can provide, and that person is unavailable. Which of the following best describes the compliance concern?
   Answer: Immediate access to compounding records is required during inspections; delayed access due to IT restrictions is a compliance issue. Compounding records must not only be retained but must be readily accessible for regulatory inspection. A system requiring unavailable personnel to provide access fails the accessibility standard. The pharmacy should have protocols ensuring records can be accessed promptly during inspections without dependency on a single point of failure. A is incorrect because electronic security features do not exempt the pharmacy from accessibility requirements. B is incorrect because records within the retention period must be accessible regardless of age. C is incorrect because accessibility during a regulatory inspection is a compliance requirement, not merely a logistical matter.
2. A pharmacy prepares the same formulation in multiple batches per week and proposes simplifying its CRs to reference the MFR rather than repeating all information. Which of the following best analyzes this proposal?
   Answer: The proposal is permissible if batch-specific details like lot numbers and QC results are still included in each CR. CRs may reference MFRs for stable, standardized information. However, batch-specific data unique to each preparation must be captured in each CR. This batch-specific data is the core purpose of the CR and cannot be replaced by an MFR reference. A is incorrect because cross-referencing between CR and MFR is an accepted practice. B is incorrect because the CR must still capture all batch-specific information. D is incorrect because the principle applies equally to both sterile and non-sterile compounding.
3. Which of the following best describes the purpose and required content of a Master Formulation Record (MFR) in compounding practice?
   Answer: The MFR contains the formula, instructions, BUD, storage, and quality control for compounded preparations. The MFR is the foundational document for each unique compounded preparation, containing the complete formula and specifications: preparation name, strength, dosage form, all ingredients and quantities, equipment and container specifications, preparation instructions, BUD assignment and its basis, storage conditions, QC procedures, and applicable safety information. Individual Compounding Records reference the MFR for each batch. B is incorrect because patient-specific information is captured in the Compounding Record or prescription record, not the MFR. C is incorrect because the MFR is a pharmacy compounding quality document, not a DEA instrument. D is incorrect because MFRs are required for all compounded preparations under both USP 795 and 797, not only sterile preparations.
4. Which of the following information must a Compounding Record (CR) include for each batch or preparation?
   Answer: Date prepared, preparation details, ingredient lot numbers, compounder and pharmacist names, beyond-use date. The CR documents the specific batch: date prepared, what was made, the lot number for traceability, quantity, specific ingredients with their lot numbers and quantities, who compounded it, who verified it, QC checks and results, and the assigned BUD. A is incorrect because formula name and pharmacist name alone are far too minimal; the CR must capture all elements listed in B. C is incorrect because patient receipt confirmation is not part of the compounding batch record. D is incorrect because billing information is not a required element of the compounding record.
5. A state board inspector requests all compounding records from the past 18 months. The pharmacist realizes that records from 14 months ago were inadvertently discarded during an office reorganization, even though they fall within the required retention period. Which of the following best analyzes the compliance concern and appropriate response?
   Answer: The pharmacist must disclose the records' destruction to the inspector, provide available records, and implement corrective measures to prevent future incidents. Record destruction within the retention period -- even if inadvertent -- is a compliance violation. The pharmacist must be forthright with the inspector, disclose the situation, provide all available records, and document the circumstances. B is incorrect because intent is not required for a record-retention violation; the obligation is to have the records. C is incorrect because the severity of a compliance violation is not determined by the proportion lost; any destruction within the retention period is a violation. D is incorrect because the pharmacist knows the records were destroyed and must disclose this; creating a false impression through delay would compound the violation.
6. Under USP Chapter 797, which of the following information is most critical to document in environmental monitoring records for a sterile compounding cleanroom?
   Answer: Sampling locations, dates, methods, CFU counts, action levels, and corrective actions for exceeded levels. USP 797 requires environmental monitoring records to document specific sampling locations, dates, methods, and results including CFU counts, whether action levels were exceeded, and corrective actions taken. This creates a longitudinal record of cleanroom environmental quality. A is incorrect because personnel entry logs are separate and are not the critical content of environmental monitoring records. B is incorrect because cost information is not a required element. C is incorrect because state board inspection history is not part of environmental monitoring records.
7. Upon receiving each shipment of bulk active pharmaceutical ingredients (APIs) for compounding, which of the following records must the pharmacy maintain?
   Answer: The supplier's Certificate of Analysis (CoA) verifying each API's identity, purity, and potency. Pharmacies sourcing bulk APIs for compounding must receive and retain a CoA from the supplier for each lot of each ingredient. The CoA documents that the ingredient meets specified identity, purity, and potency standards, and is required to demonstrate that the pharmacy used ingredients of appropriate quality. A is incorrect because a purchase invoice alone does not document quality specifications. B is incorrect because not all bulk APIs are controlled substances; DEA Form 222 applies only to Schedule I and II controlled substance ordering. D is incorrect because visual inspection cannot assess identity, purity, or potency; the CoA is required.
8. A 503B outsourcing facility is inspected by the FDA. The investigator requests compounding records for a batch distributed six months ago. The facility provides the CR but cannot locate the MFR because a server crashed and the backup failed. Which of the following best analyzes the facility's situation?
   Answer: The missing MFR is a significant compliance issue as 503B facilities must maintain complete batch records under cGMP requirements. 503B outsourcing facilities are subject to cGMP requirements including comprehensive document control obligations. The MFR is not supplementary; it is an essential component of the batch documentation system. A server failure resulting in permanent document loss demonstrates failure of document control and backup systems, both of which are cGMP findings. A is incorrect because the CR and MFR serve different purposes and the CR alone cannot reconstruct the MFR's complete specifications. B is incorrect because records must be retained and accessible throughout the applicable retention period. C is incorrect because both the MFR and CR are required compounding documents of equal importance.
9. A pharmacist performs weight checks and pH testing as quality control measures on a non-sterile compounded preparation. Where must the results of these QC tests be documented?
   Answer: QC results must be documented in the Compounding Record for the batch, including the specific tests performed, results obtained, and whether results met the acceptance criteria. QC test results must be documented in the CR for each batch, capturing what tests were performed, the results obtained, and whether those results met the acceptance criteria defined in the MFR. A is incorrect because QC documentation is a required element of the CR, not optional. B is incorrect because QC results belong in the compounding records, specifically the CR, not the patient prescription record. D is incorrect because the MFR contains the QC procedure specifications while the CR documents the actual QC results for each specific batch.
10. Which of the following records must a pharmacy maintain related to the periodic certification of a laminar airflow workbench used for sterile compounding?
    Answer: Certification records including date, certifier qualifications, test results, and pass/fail status. The pharmacy must maintain detailed certification records for cleanroom equipment. These records must document the date, certifier information, actual test results including airflow velocities and particle counts, acceptance criteria, and the next certification due date. B is incorrect because specific test values are required, not merely the pass or fail outcome. C is incorrect because the pharmacy bears the record-retention obligation; contractor records are not a substitute. D is incorrect because certification records must be maintained whether equipment passes or fails; failure records are particularly important as they trigger corrective action requirements.
11. During an inspection, an investigator finds that the CR for a batch of sterile eye drops does not include gloved fingertip sampling results for the preparing technician. The pharmacist explains the results were performed and filed in the personnel competency file. Which of the following best analyzes this situation?
    Answer: There is no compliance concern; under USP 797, gloved fingertip sampling results are personnel competency documentation and are appropriately maintained in personnel files rather than in the batch Compounding Record. Under USP Chapter 797, gloved fingertip sampling is a personnel competency assessment that must be documented in personnel competency records. It is not a batch-specific quality test that belongs in the Compounding Record. Gloved fingertip sampling assesses whether a compounder's garbing and aseptic technique result in acceptable microbial counts on their gloves; this is ongoing personnel-level documentation, not a per-batch quality check. Maintaining these results in a personnel competency file is the correct practice. A is incorrect because not all pharmacy documentation is required to be in or referenced by the CR; personnel competency records are a distinct documentation category. C is incorrect because USP 797 does not require per-batch cross-referencing of gloved fingertip results in the CR; the results belong in personnel files. D is incorrect because gloved fingertip sampling applies to all sterile compounding personnel including technicians, not only pharmacists.
12. During an inspection, an investigator finds that a pharmacy's Compounding Records do not include the lot numbers of the ingredients used. The pharmacist states that lot numbers are available in the pharmacy's purchase records. Which of the following best describes the compliance concern?
    Answer: This is a compliance violation; lot numbers must be directly documented in the Compounding Record. Including ingredient lot numbers in the CR is a core requirement for traceability. The purpose is to enable rapid identification of the specific lots used in a preparation -- essential for recall investigations. Requiring cross-referencing with separate purchase documents defeats this purpose. A is incorrect because lot numbers must be in the CR itself; availability elsewhere is not a substitute. B is incorrect because lot number tracking applies to all ingredients, not only controlled substances. C is incorrect because past records that are incomplete constitute existing violations; they cannot be corrected prospectively.
13. A recall is initiated for a bulk API lot used by a compounding pharmacy. The pharmacy needs to determine which batches used this ingredient lot and which patients received those preparations. Which compounding records are essential to this recall investigation?
    Answer: Compounding records linking ingredient lot numbers to batch numbers and dispensing records to identify affected patients. An effective recall investigation requires a complete documentation chain: the CR must link the recalled ingredient lot number to the specific batch number, and dispensing records must link that batch number to specific patients. Without this chain, the pharmacy cannot identify affected patients. A is incorrect because patient prescription records alone do not identify which ingredient lots were used; the CRs provide this link. B is incorrect because the MFR contains the formula template but does not document which ingredient lots were used in each batch; the CR provides that. D is incorrect because the pharmacy's records are essential to retail-level recall investigation.
14. Under most pharmacy regulations and USP standards, what is the minimum retention period for compounding records?
    Answer: 3 years from the date of compounding or dispensing, per USP standards. Current USP Chapter 795 and Chapter 797 standards require compounding records to be retained for a minimum of 3 years from the date of compounding or the beyond-use date, whichever is later. State pharmacy laws may require longer retention periods. A is incorrect because 6 months is far below the USP minimum. B is incorrect because 1 year is also below the USP minimum. D is incorrect because indefinite retention is not the legal standard; the USP 3-year minimum applies, with longer periods where required by state law.
15. When a controlled substance is used as an ingredient in a compounded preparation, what additional DEA-specific documentation is required beyond the standard Compounding Record?
    Answer: The controlled substance quantity used must be documented in the pharmacy's inventory records for reconciliation purposes. DEA recordkeeping requirements apply in addition to state compounding recordkeeping requirements when controlled substances are used as ingredients. The pharmacy must maintain records that account for all controlled substances received and used, enabling complete inventory reconciliation. A is incorrect because the CR alone does not automatically satisfy DEA controlled substance accounting requirements. C is incorrect because DEA Form 222 is used for ordering Schedule I and II substances, not for documenting individual compounding uses. D is incorrect because the DEA does not require notification each time a controlled substance is used in compounding.
16. A software update inadvertently changes the timestamps on several historical CRs in a pharmacy's electronic system, making them appear to have been created after the preparations were actually compounded. The pharmacy discovers this after a routine audit. Which of the following best analyzes the pharmacy's obligations?
    Answer: The pharmacy must document the error, preserve original records with explanations, and notify authorities if required, without altering or deleting the affected records. Records must not be altered or deleted to conceal errors, even inadvertent ones. The appropriate response is to document the incident, preserve the original records with an explanatory annotation, and address the root cause. Deleting or altering records is falsification regardless of intent. A is incorrect because deleting and recreating records is falsification; the original records and the error must be preserved. C is incorrect because directly altering timestamps, even to restore accuracy, creates audit trail integrity concerns and may constitute falsification. D is incorrect because timestamps are substantive metadata establishing when records were created, which is material to compounding compliance.
17. A pharmacy has used the same MFR for a topical cream formulation for three years. An updated edition of USP 795 changes the BUD requirements for this formulation category, but the pharmacist continues using the old MFR without updating it. Which of the following best analyzes the compliance concern?
    Answer: The pharmacy must update the MFR to reflect current USP 795 standards to ensure compliance with BUD requirements. MFRs must be updated when applicable standards change. An MFR based on superseded USP standards generates CRs with non-compliant BUDs. The pharmacy has an ongoing obligation to maintain current and accurate MFRs. A is incorrect because there is no grandfather provision for outdated formulation standards; the obligation to comply with current standards is continuous. C is incorrect because USP 795 standards are incorporated by reference into most state pharmacy laws and are enforceable. D is incorrect because the compliance obligation applies regardless of whether the new BUD is shorter or longer.
18. Under USP Chapter 797, which of the following represents required personnel competency assessments that must be documented in personnel records for sterile compounding?
    Answer: Successful completion of media fill testing demonstrating aseptic technique, gloved fingertip sampling with acceptable results, and documented training in garbing procedures. USP 797 requires documented personnel competency assessments including media fill testing to demonstrate aseptic technique, gloved fingertip sampling after garbing to assess contamination risk, and documented training in donning and doffing personal protective equipment. These must be performed initially and repeated periodically. B is incorrect because pharmacist license renewal is a state licensure matter unrelated to sterile compounding competency documentation. C is incorrect because a written examination alone is insufficient; procedural competency assessments including media fills and gloved fingertip sampling are required. D is incorrect because work experience alone does not satisfy the documented competency assessment requirement.
19. A pharmacy receives a shipment of bulk API and begins using it in compounding without obtaining the Certificate of Analysis (CoA). During an inspection, the investigator asks for the CoA and the pharmacy cannot produce it. Which of the following best describes the compliance concern?
    Answer: Compounding without a CoA violates USP standards requiring verification of identity, purity, and potency of bulk drug substances. USP compounding standards (795, 797) require pharmacies to obtain CoAs for bulk substances and verify ingredient identity and purity before use. The CoA is the primary documentation that the ingredient meets quality specifications. B is incorrect because FDA supplier registration confirms manufacturing facility compliance but does not substitute for a lot-specific CoA. C is incorrect because visual inspection cannot assess identity, purity, or potency. D is incorrect because CoA requirements apply to both non-sterile (USP 795) and sterile (USP 797) compounding.
20. A pharmacist prepares a batch of oral suspension and records the assigned BUD of 14 days and the required storage conditions in the CR, but does not include the rationale or reference source for the BUD assignment in the CR itself. That information is fully documented in the Master Formulation Record. Which of the following best describes the compliance concern?
    Answer: No compliance issue exists; USP 795 requires BUD and storage conditions in the CR, with rationale documented in the MFR. Under current USP 795, the Master Formulation Record is the document that must contain the BUD reference source and the basis for BUD assignment. The Compounding Record is required to document the assigned BUD and storage requirements for each specific batch. Because both the assigned BUD and storage conditions are present in the CR, and the basis is appropriately located in the MFR, the pharmacy's practice is compliant. A is incorrect because while the BUD is present, storage requirements are also required in the CR -- though the scenario states both are present, making this a misdirection. B is incorrect because a full stability study citation in the CR is not required; the assigned BUD and storage conditions are the CR elements, with the reference basis residing in the MFR. D is incorrect because USP 795 does not require duplication of the BUD basis in both documents; the MFR is the appropriate location for that information.

Start this quiz